The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
After finishing at $8.47 in the prior trading day, Biocryst Pharmaceuticals Inc (NASDAQ: BCRX) closed at $8.31, down -1.89%. In other words, the price has decreased by -$1.89 from its previous closing price. On the day, 2.31 million shares were traded. BCRX stock price reached its highest trading level at $8.49 during the session, while it also had its lowest trading level at $8.29.
Ratios:
Our goal is to gain a better understanding of BCRX by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 6.70 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 112.54. For the most recent quarter (mrq), Quick Ratio is recorded 2.22 and its Current Ratio is at 2.25.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Cantor Fitzgerald on April 29, 2025, initiated with a Overweight rating and assigned the stock a target price of $20.
On February 25, 2025, Wedbush started tracking the stock assigning an Outperform rating and target price of $15.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Aug 13 ’25 when HEGGIE THERESA sold 70,000 shares for $8.51 per share. The transaction valued at 595,868 led to the insider holds 65,352 shares of the business.
HEGGIE THERESA bought 70,000 shares of BCRX for $595,871 on Aug 13 ’25. On Dec 13 ’24, another insider, Hutson Nancy J, who serves as the Director of the company, sold 7,000 shares for $7.54 each. As a result, the insider received 52,780 and left with 86,638 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BCRX now has a Market Capitalization of 1744435328 and an Enterprise Value of 2223317760. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.13. Its current Enterprise Value per Revenue stands at 3.988 whereas that against EBITDA is 38.001.
Stock Price History:
The Beta on a monthly basis for BCRX is 1.13, which has changed by 0.0072727203 over the last 52 weeks, in comparison to a change of 0.16844666 over the same period for the S&P500. Over the past 52 weeks, BCRX has reached a high of $11.31, while it has fallen to a 52-week low of $6.01. The 50-Day Moving Average of the stock is -4.37%, while the 200-Day Moving Average is calculated to be -1.77%.
Shares Statistics:
The stock has traded on average 3.28M shares per day over the past 3-months and 2006310 shares per day over the last 10 days, according to various share statistics. A total of 209.91M shares are outstanding, with a floating share count of 202.70M. Insiders hold about 3.44% of the company’s shares, while institutions hold 93.59% stake in the company. Shares short for BCRX as of 1755216000 were 27082099 with a Short Ratio of 8.26, compared to 1752537600 on 26779523. Therefore, it implies a Short% of Shares Outstanding of 27082099 and a Short% of Float of 12.950000000000001.
Earnings Estimates
The stock of Biocryst Pharmaceuticals Inc (BCRX) is currently drawing attention from 4.0 analysts actively involved in the ongoing evaluation and rating process.The consensus estimate for the next quarter is $0.03, with high estimates of $0.04 and low estimates of $0.02.
Analysts are recommending an EPS of between $0.36 and $0.06 for the fiscal current year, implying an average EPS of $0.15. EPS for the following year is $0.45, with 5.0 analysts recommending between $0.8 and $0.3.
Revenue Estimates
9 analysts predict $162.24M in revenue for the current quarter. It ranges from a high estimate of $166.22M to a low estimate of $156M. As of the current estimate, Biocryst Pharmaceuticals Inc’s year-ago sales were $117.08MFor the next quarter, 9 analysts are estimating revenue of $155.74M. There is a high estimate of $162.08M for the next quarter, whereas the lowest estimate is $147.98M.
A total of 9 analysts have provided revenue estimates for BCRX’s current fiscal year. The highest revenue estimate was $631.12M, while the lowest revenue estimate was $611.65M, resulting in an average revenue estimate of $625.38M. In the same quarter a year ago, actual revenue was $450.71MBased on 9 analysts’ estimates, the company’s revenue will be $669.41M in the next fiscal year. The high estimate is $702M and the low estimate is $637.68M.
